Scarica l'app Stockscreener
1.715
3.92%
0.055
Precedente Chiudi:
$1.66
Aprire:
$1.68
Volume 24 ore:
1.53M
Relative Volume:
0.96
Capitalizzazione di mercato:
$395.06M
Reddito:
$8.95M
Utile/perdita netta:
$-21.49M
Rapporto P/E:
-14.29
EPS:
-0.12
Flusso di cassa netto:
$-29.24M
1 W Prestazione:
+0.88%
1M Prestazione:
+28.73%
6M Prestazione:
+267.18%
1 anno Prestazione:
+101.66%
Intervallo 1D:
$1.645
$1.74
Intervallo di 1 settimana:
$1.63
$1.83
Portata 52W:
$0.3651
$1.83
Lineage Cell Therapeutics Inc Stock (LCTX) Company Profile
Nome
Lineage Cell Therapeutics Inc
Settore
Industria
Telefono
510-871-4188
Indirizzo
2173 Salk Avenue, Suite 200, Carlsbad, CA
Confronta LCTX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LCTX
Lineage Cell Therapeutics Inc
|
1.73 | 379.07M | 8.95M | -21.49M | -29.24M | -0.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.18 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
471.62 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
552.36 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
808.25 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
331.09 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Lineage Cell Therapeutics Inc Stock (LCTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-08-20 | Iniziato | Craig Hallum | Buy |
| 2022-11-02 | Iniziato | Robert W. Baird | Outperform |
| 2022-06-14 | Iniziato | B. Riley Securities | Buy |
| 2021-08-19 | Iniziato | Noble Capital Markets | Outperform |
| 2021-03-31 | Iniziato | Cantor Fitzgerald | Overweight |
Lineage Cell Therapeutics Inc Borsa (LCTX) Ultime notizie
What the charts say about Lineage Cell Therapeutics Inc. todayJuly 2025 Intraday Action & Precise Entry and Exit Recommendations - newser.com
Analyzing drawdowns of Lineage Cell Therapeutics Inc. with statistical tools - newser.com
Why Lineage Cell Therapeutics Inc. stock remains undervaluedGap Down & Comprehensive Market Scan Insights - newser.com
How institutional ownership impacts Lineage Cell Therapeutics Inc. stockDay Trade & Breakout Confirmation Trade Signals - newser.com
Developing predictive dashboards with Lineage Cell Therapeutics Inc. data2025 Earnings Impact & Reliable Breakout Stock Forecasts - newser.com
Can Lineage Cell Therapeutics Inc. stock ride next bull market cycleWeekly Investment Report & Weekly Hot Stock Watchlists - newser.com
How Lineage Cell Therapeutics Inc. stock reacts to Fed tighteningJuly 2025 PreEarnings & Long Hold Capital Preservation Plans - newser.com
Applying sector rotation models to Lineage Cell Therapeutics Inc.Risk Management & Expert Approved Momentum Trade Ideas - newser.com
Can Lineage Cell Therapeutics Inc. stock withstand economic slowdownTrade Risk Assessment & Long-Term Safe Investment Ideas - newser.com
Lineage Cell Therapeutics Hits New 52-Week High of $1.82 - Markets Mojo
Can Lineage Cell Therapeutics Inc. stock maintain operating marginsPortfolio Return Summary & Risk Controlled Stock Pick Alerts - newser.com
Long term hold vs stop loss in Lineage Cell Therapeutics Inc.2025 Top Decliners & Smart Swing Trading Techniques - newser.com
Spinal Cord Injury Market Positioned for Accelerated Development Through 2034, DelveInsight Finds | Kringle Pharma, Neuroplast, Abbvie, Mitsubishi Tanabe Pharma, Lineage Cell Therapeutics, NervGen - Barchart.com
Stem Cell Therapy Market Forecast to 2033: Growth Driven - openPR.com
Key resistance and support levels for Lineage Cell Therapeutics Inc.2025 Growth vs Value & Low Risk Profit Maximizing Plans - newser.com
What technical models suggest about Lineage Cell Therapeutics Inc.’s comebackMarket Sentiment Report & Safe Swing Trade Setups - newser.com
Can Lineage Cell Therapeutics Inc. hit a new high this monthSell Signal & Verified Short-Term Trading Plans - newser.com
What analysts say about Lineage Cell Therapeutics Inc stockSector Rotation Strategies & Minimal Capital Growth Plans - earlytimes.in
Can momentum traders help lift Lineage Cell Therapeutics Inc.New Guidance & Community Trade Idea Sharing - newser.com
Price momentum metrics for Lineage Cell Therapeutics Inc. explained2025 Key Lessons & Weekly Top Gainers Trade List - newser.com
Is Lineage Cell Therapeutics Inc. stock cheap vs fundamentalsJuly 2025 WrapUp & Daily Profit Focused Stock Screening - newser.com
Using R and stats models for Lineage Cell Therapeutics Inc. forecastingJuly 2025 Price Swings & Community Trade Idea Sharing Platform - newser.com
Advanced analytics toolkit walkthrough for Lineage Cell Therapeutics Inc.2025 Risk Factors & AI Based Trade Execution Alerts - newser.com
Using data tools to time your Lineage Cell Therapeutics Inc. exitWeekly Trade Summary & Growth-Oriented Investment Plans - newser.com
Goldman Sachs Group Inc. Sells 34,963 Shares of Lineage Cell Therapeutics, Inc. $LCTX - Defense World
Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Trading Up 4.7%Should You Buy? - MarketBeat
Lineage Cell Therapeutics Hits New 52-Week High of $1.72 - Markets Mojo
Lineage Cell Therapeutics Inc Azioni (LCTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.86%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):